Robert L. Coleman
Expertise in
1
conditions

Dr. Robert L. Coleman

Plastic Surgery
7301 Mission Rd, Suite #240, 
Prairie Village, KS 
Expertise in
1
conditions
7301 Mission Rd, Suite #240, 
Prairie Village, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Coleman is a Plastic Surgeon in Prairie Village, Kansas. Dr. Coleman is highly rated in 1 condition, according to our data. His top areas of expertise are Fractured Spine, Menopause, Endoscopy, and Lymphadenectomy.

His clinical research consists of co-authoring 412 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Plastic Surgery
Licenses
Plastic Surgery in KS
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

7301 Mission Rd, Suite #240, Prairie Village, KS 66208

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition
EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drugs: Adavosertib, Olaparib
Study Phase: Phase 2
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 1
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Bevacizumab, Emactuzumab, Paclitaxel
Study Phase: Phase 2
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Enrollment Status: Unknown
Publish Date: January 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Paclitaxel
Study Phase: Phase 2
View 8 Less Clinical Trials

412 Total Publications

Corrigendum to "First-line treatments for advanced or recurrent endometrial cancer: Systemic literature review of clinical evidence" [Crit. Rev. Oncol./Hematol. 206 (2025) 104555].
Corrigendum to "First-line treatments for advanced or recurrent endometrial cancer: Systemic literature review of clinical evidence" [Crit. Rev. Oncol./Hematol. 206 (2025) 104555].
Journal: Critical reviews in oncology/hematology
Published: August 12, 2025
Similar Doctors
Expertise in
6
conditions
Dr. Eric C. Swanson
Plastic Surgery
Expertise in
6
conditions
Dr. Eric C. Swanson
Plastic Surgery
Leawood, KS 
 (4.9 miles away)
913-663-1030
Languages Spoken:
English
See accepted insurances

Eric Swanson is a Plastic Surgeon in Leawood, Kansas. Dr. Swanson is highly rated in 6 conditions, according to our data. His top areas of expertise are Venous Thromboembolism (VTE), T-Cell Lymphoma, Ptosis, Abdominal Wall Surgery, and Fasciotomy.

Expertise in
26
conditions
Dr. Yelizaveta L. Shnayder
Plastic Surgery | Otolaryngology
Expertise in
26
conditions
Dr. Yelizaveta L. Shnayder
Plastic Surgery | Otolaryngology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (4.3 miles away)
913-588-1227
Languages Spoken:
English, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Yelizaveta Shnayder is a Plastic Surgeon and an Otolaryngologist in Kansas City, Kansas. Dr. Shnayder is highly rated in 26 conditions, according to our data. Her top areas of expertise are Oral Squamous Cell Carcinoma, Acinic Cell Carcinoma of Salivary Glands, Salivary Gland Tumors, Gastrostomy, and Laryngectomy. Dr. Shnayder is currently accepting new patients.

Robert F. Thompson
Expertise in
43
conditions
Dr. Robert F. Thompson
Plastic Surgery | Otolaryngology
Expertise in
43
conditions
Dr. Robert F. Thompson
Plastic Surgery | Otolaryngology

Head And Neck Surgery Of Kansas City

5370 College Blvd, Ste 100, 
Overland Park, KS 
 (4.9 miles away)
913-599-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Thompson is a Plastic Surgeon and an Otolaryngologist in Overland Park, Kansas. Dr. Thompson is highly rated in 43 conditions, according to our data. His top areas of expertise are Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Neonatal Severe Hyperparathyroidism, Familial Isolated Hyperparathyroidism, Osteitis Fibrosa, and Myringotomy. Dr. Thompson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Coleman's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile